Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.

Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, Boyer-Chammard T, Chen T, Dromer F, Hlupeni A, Hope W, Hosseinipour MC, Kanyama C, Lortholary O, Loyse A, Meya DB, Mosepele M, Muzoora C, Mwandumba HC, Ndhlovu CE, Niessen L, Schutz C, Stott KE, Wang D, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN.

Trials. 2019 Jan 14;20(1):48. doi: 10.1186/s13063-018-3155-9.

2.

Correction for Stott et al., "Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis".

Stott KE, Beardsley J, Kolamunnage-Dona R, Castelazo AS, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Day J, Hope W.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02254-18. doi: 10.1128/AAC.02254-18. Print 2018 Dec. No abstract available.

3.

Correction for Stott et al., "Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis".

Stott KE, Beardsley J, Whalley S, Mukasa Kibengo F, Mai NTH, Tùng NLN, Cuc NTK, Kolamunnage-Dona R, Hope W, Day J.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02249-18. doi: 10.1128/AAC.02249-18. Print 2018 Dec. No abstract available.

4.

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.

Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, Boyer-Chammard T, Chen T, Dromer F, Hlupeni A, Hope W, Hosseinipour MC, Kanyama C, Lortholary O, Loyse A, Meya DB, Mosepele M, Muzoora C, Mwandumba HC, Ndhlovu CE, Niessen L, Schutz C, Stott KE, Wang D, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN.

Trials. 2018 Nov 23;19(1):649. doi: 10.1186/s13063-018-3026-4. Erratum in: Trials. 2019 Jan 14;20(1):48.

5.

Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system.

Stott KE, Hope W.

Expert Opin Drug Metab Toxicol. 2018 Aug;14(8):803-815. doi: 10.1080/17425255.2018.1492551. Epub 2018 Jul 9. Review.

PMID:
29943650
6.

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis.

Stott KE, Beardsley J, Kolamunnage-Dona R, Castelazo AS, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Day J, Hope W.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00885-18. doi: 10.1128/AAC.00885-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

7.

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.

Stott KE, Beardsley J, Whalley S, Kibengo FM, Mai NTH, Tùng NLN, Cuc NTK, Kolamunnage-Dona R, Hope W, Day J.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02526-17. doi: 10.1128/AAC.02526-17. Print 2018 Jul. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

8.

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G.

J Antimicrob Chemother. 2018 Sep 1;73(9):2305-2313. doi: 10.1093/jac/dky152.

9.

PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES.

Hyatt MW, Wiederhold NP, Hope WW, Stott KE.

J Zoo Wildl Med. 2017 Jun;48(2):352-362. doi: 10.1638/2016-0160R2.1.

PMID:
28749255
10.

Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.

Stott KE, Hope WW.

J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i12-i18. doi: 10.1093/jac/dkx029. Review.

PMID:
28355463
11.

Clostridium difficile: A healthcare-associated infection of unknown significance in adults in sub-Saharan Africa.

Keeley AJ, Beeching NJ, Stott KE, Roberts P, Watson AJ, Beadsworth MB.

Malawi Med J. 2016 Jun;28(2):66-69. Review.

12.

Adequacy of Rifampin Absorption after Jejunostomy Tube Administration.

Stott KE, Singh B, Beadsworth MB, Vaudrey K, Khoo SH, Davies G.

Pharmacotherapy. 2016 Apr;36(4):e23-5. doi: 10.1002/phar.1730. Epub 2016 Apr 6.

13.

Brief Report: Virologic Monitoring Can Be a Cost-Effective Strategy to Diagnose Treatment Failure on First-Line ART.

Vandormael AM, Boulware DR, Tanser FC, Bärnighausen TW, Stott KE, de Oliveira T.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):462-6. doi: 10.1097/QAI.0000000000000870.

14.

Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort.

Lewis JM, Stott KE, Monnery D, Seden K, Beeching NJ, Chaponda M, Khoo S, Beadsworth MB.

Int J STD AIDS. 2016 Feb;27(2):105-9. doi: 10.1177/0956462415574632. Epub 2015 Feb 25.

PMID:
25721922
15.

Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges.

Lessells RJ, Stott KE, Manasa J, Naidu KK, Skingsley A, Rossouw T, de Oliveira T; Southern African Treatment and Resistance Network (SATuRN).

BMC Health Serv Res. 2014 Mar 7;14:116. doi: 10.1186/1472-6963-14-116.

16.

Combined antiretroviral and anti-tuberculosis drug resistance following incarceration.

Stott KE, de Oliviera T, Lessells RJ.

South Afr J HIV Med. 2013 Sep 1;14(3). doi: 10.7196/SAJHIVMED.957.

Supplemental Content

Loading ...
Support Center